Literature DB >> 16402288

A new approach to modeling covariate effects and individualization in population pharmacokinetics-pharmacodynamics.

Tze Leung Lai1, Mei-Chiung Shih, Samuel P Wong.   

Abstract

By combining Laplace's approximation and Monte Carlo methods to evaluate multiple integrals, this paper develops a new approach to estimation in nonlinear mixed effects models that are widely used in population pharmacokinetics and pharmacodynamics. Estimation here involves not only estimating the model parameters from Phase I and II studies but also using the fitted model to estimate the concentration versus time curve or the drug effects of a subject who has covariate information but sparse measurements. Because of its computational tractability, the proposed approach can model the covariate effects nonparametrically by using (i) regression splines or neural networks as basis functions and (ii) AIC or BIC for model selection. Its computational and statistical advantages are illustrated in simulation studies and in Phase I trials.

Mesh:

Substances:

Year:  2006        PMID: 16402288     DOI: 10.1007/s10928-005-9000-2

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  13 in total

1.  Assessment of actual significance levels for covariate effects in NONMEM.

Authors:  U Wählby; E N Jonsson; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

2.  Assessment of type I error rates for the statistical sub-model in NONMEM.

Authors:  Ulrika Wählby; M René Bouw; E Niclas Jonsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-06       Impact factor: 2.745

3.  Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine.

Authors:  M Davidian; A R Gallant
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

4.  A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam.

Authors:  P O Maitre; M Bührer; D Thomson; D R Stanski
Journal:  J Pharmacokinet Biopharm       Date:  1991-08

5.  A use of Monte Carlo integration for population pharmacokinetics with multivariate population distribution.

Authors:  A Yafune; M Takebe; H Ogata
Journal:  J Pharmacokinet Biopharm       Date:  1998-02

6.  A new method to explore the distribution of interindividual random effects in non-linear mixed effects models.

Authors:  K E Fattinger; L B Sheiner; D Verotta
Journal:  Biometrics       Date:  1995-12       Impact factor: 2.571

7.  Handling covariates in population pharmacokinetics.

Authors:  F Mentré; A Mallet
Journal:  Int J Biomed Comput       Date:  1994-06

8.  Statistical analysis of ligand-binding experiments.

Authors:  T L Lai; L Zhang
Journal:  Biometrics       Date:  1994-09       Impact factor: 2.571

9.  Population pharmacokinetics of temozolomide in cancer patients.

Authors:  J F Jen; D L Cutler; S M Pai; V K Batra; M B Affrime; D N Zambas; S Heft; G Hajian
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

10.  Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).

Authors:  E S Newlands; G R Blackledge; J A Slack; G J Rustin; D B Smith; N S Stuart; C P Quarterman; R Hoffman; M F Stevens; M H Brampton
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

View more
  1 in total

1.  Nonparametric goodness-of-fit testing for parametric covariate models in pharmacometric analyses.

Authors:  Niklas Hartung; Martin Wahl; Abhishake Rastogi; Wilhelm Huisinga
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-06-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.